Besides EGFR, ALK, KRAS, ROS1, c-MET, and PIK3CA have been implicated as a driver of NSCLCs, such as crizotinib for ALK‐positive lung cancer patients (1, 2). The gene discussed is ALK; the disease is lung cancer.